Kiyoshi Yoshimura 研究室

主宰者：Kiyoshi Yoshimura

昭和大学

AI 要約（直近 5 年の研究成果）

吉村研究室では、がん免疫療法の効果を予測し、治療成績を向上させるための研究に取り組んでいます。特に、抗PD-1抗体などの免疫チェックポイント阻害薬（ICI）に対する患者の反応は個人差が大きいという臨床課題に着目し、その反応性を規定する要因を多角的に解明することを目指しています。具体的には、腫瘍浸潤リンパ球や末梢血中のT細胞における抗体結合の程度、血液中の免疫グロブリンや炎症関連物質の濃度、骨格筋量などの全身性指標を測定し、ICI治療の効果予測との関連性を検討しています。さらに、腸内細菌叢の構成や機能がICI効果に与える影響を詳しく調べており、特定の菌種や細菌代謝産物が治療効果を強化する可能性を検証しています。マウス腫瘍モデルを用いた基礎実験と患者データの解析を組み合わせることで、ICI治療を受ける患者を層別化し、より適切な治療戦略を提案することを目指しています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（62 件）

[2026] Additional file 6 of Cetirizine suppresses cancer-associated fibroblast-mediated fibrotic remodeling and epithelial–mesenchymal transition via histamine H1 receptor inverse agonism
DOI: https://doi.org/10.6084/m9.figshare.32752135
[2026] Elevated plasma IgG is associated with improved treatment response and survival in advanced non‑small cell lung cancer patients treated with anti‑PD‑1 therapy
DOI: https://doi.org/10.1038/s41598-026-46923-x
[2026] Longitudinal analysis of PD-1 receptor occupancy in spleen and tumor-infiltrating lymphocytes in a murine model.
DOI: https://doi.org/10.1200/jco.2026.44.16_suppl.e14580
[2026] Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP
DOI: https://doi.org/10.3389/fimmu.2026.1832317
[2026] Cetirizine suppresses cancer-associated fibroblast-mediated fibrotic remodeling and epithelial–mesenchymal transition via histamine H1 receptor inverse agonism
DOI: https://doi.org/10.1186/s13058-026-02284-x
[2026] Additional file 6 of Cetirizine suppresses cancer-associated fibroblast-mediated fibrotic remodeling and epithelial–mesenchymal transition via histamine H1 receptor inverse agonism
DOI: https://doi.org/10.6084/m9.figshare.32752135.v1
[2025] Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study
DOI: https://doi.org/10.3390/biomedicines13123029
[2025] Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression
DOI: https://doi.org/10.3389/fimmu.2025.1528594
[2025] Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
DOI: https://doi.org/10.1007/s00262-025-04111-2
[2025] Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study
DOI: https://doi.org/10.3390/cancers17142384

続きを表示（残り 52 件）

[2025] Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers
DOI: https://doi.org/10.3389/fonc.2025.1614102
[2025] Combination therapy with levofloxacin and the probiotic <i>Clostridium butyricum</i><scp>MIYAIRI</scp> 588 enhances immune checkpoint inhibitor efficacy
DOI: https://doi.org/10.1002/ijc.35472
[2025] Association between the <i>ABCC11</i> gene polymorphism-determined earwax properties and external auditory canal microbiota in healthy adults
DOI: https://doi.org/10.1128/spectrum.01698-24
[2025] Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors
DOI: https://doi.org/10.3389/fimmu.2025.1528521
[2025] Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in mice
DOI: https://doi.org/10.1016/j.ejphar.2025.177704
[2025] Intestinal and esophageal microbiota in esophageal cancer development and treatment
DOI: https://doi.org/10.1080/19490976.2025.2505118
[2025] Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma
DOI: https://doi.org/10.21873/anticanres.17579
[2025] Implications of Nurse-led Screening for COVID-19 in Patients Receiving Cancer Drug Therapy
DOI: https://doi.org/10.4993/acrt.33.42
[2025] Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
DOI: https://doi.org/10.3389/fonc.2025.1499650
[2025] Ki-67 expression in anti-programmed cell death protein-1 antibody-bound CD8+ T cells as a predictor of clinical benefit
DOI: https://doi.org/10.1007/s12672-025-02060-x
[2025] Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study
DOI: https://doi.org/10.3389/fimmu.2025.1640603
[2024] Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report
DOI: https://doi.org/10.4251/wjgo.v16.i2.557
[2024] Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
DOI: https://doi.org/10.1038/s41598-024-59677-1
[2024] Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors
DOI: https://doi.org/10.21873/cgp.20481
[2024] Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice
DOI: https://doi.org/10.1016/j.biopha.2024.117749
[2024] Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients
DOI: https://doi.org/10.3389/fonc.2024.1449941
[2024] MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2DLow T cells
DOI: https://doi.org/10.1038/s41598-024-73712-1
[2024] Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment
DOI: https://doi.org/10.21873/anticanres.17160
[2024] Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience
DOI: https://doi.org/10.21873/anticanres.17003
[2024] Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer
DOI: https://doi.org/10.1007/s00262-023-03608-y
[2024] Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit
DOI: https://doi.org/10.1111/cas.16061
[2023] Association of microbiota with cancer treatment
DOI: https://doi.org/10.1007/s10147-023-02302-4
[2023] Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model
DOI: https://doi.org/10.21873/anticanres.16784
[2023] Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit
DOI: https://doi.org/10.1254/jpssuppl.97.0_2-b-yia5-5
[2023] The tumor immune microenvironment in pancreatic cancer and its potential in the identification of immunotherapy biomarkers
DOI: https://doi.org/10.1080/14737159.2023.2281482
[2023] 149P A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
DOI: https://doi.org/10.1016/j.annonc.2023.10.284
[2023] Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors
DOI: https://doi.org/10.3389/fimmu.2023.1260492
[2023] Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
DOI: https://doi.org/10.1136/jitc-2023-007126
[2023] Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
DOI: https://doi.org/10.3892/ol.2023.13967
[2023] Association between pH regulation of the tumor microenvironment and immunological state
DOI: https://doi.org/10.3389/fonc.2023.1175563
[2023] Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary
DOI: https://doi.org/10.3389/fonc.2023.1231986
[2023] Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
DOI: https://doi.org/10.3389/fimmu.2023.1164724
[2022] Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors
DOI: https://doi.org/10.3390/life12081229
[2022] Current Status of Immune Checkpoint Inhibitors in the Broncho-Esophagological Field
DOI: https://doi.org/10.2468/jbes.73.308
[2022] ASO Visual Abstract: Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells
DOI: https://doi.org/10.1245/s10434-022-12425-z
[2022] Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells
DOI: https://doi.org/10.1186/s12885-022-09370-1
[2022] Verification of the Usefulness of an Assessment and Risk Control Sheet that Promotes Management of Cancer Drug Therapy
DOI: https://doi.org/10.3389/fphar.2022.744916
[2022] Gut microbiota associate with recurrence of cancer after surgery in colorectal cancer patients.
DOI: https://doi.org/10.1254/jpssuppl.95.0_2-yia-57
[2022] Immunological effects of inosine, a metabolite from gut microbiota, in the tumor microenvironment
DOI: https://doi.org/10.1254/jpssuppl.95.0_2-o-052
[2022] NKG2D-high T cells are able to be activated regardless of the level of NKG2D ligands expression
DOI: https://doi.org/10.1254/jpssuppl.95.0_2-o-051
[2022] Immunological Modification of the Head and Neck Cancer Microenvironment by Short Chain Fatty Acids
DOI: https://doi.org/10.1254/jpssuppl.95.0_2-o-053
[2022] Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells
DOI: https://doi.org/10.1245/s10434-022-12220-w
[2021] Reduced expression of programmed cell death 1 and programmed cell death ligand 1 in infiltrating inflammatory cells of lichen planus without administration of immune checkpoint inhibitors
DOI: https://doi.org/10.1111/1346-8138.15977
[2021] The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer
DOI: https://doi.org/10.1097/mpa.0000000000001731
[2021] Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
DOI: https://doi.org/10.3390/biomedicines9121929
[2021] Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer
DOI: https://doi.org/10.21873/invivo.12449
[2021] Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance
DOI: https://doi.org/10.1097/mpa.0000000000001772
[2021] Calcium/calmodulin-dependent regulation of Rac GTPases and Akt in histamine-induced chemotaxis of mast cells
DOI: https://doi.org/10.1016/j.cellsig.2021.109973
[2021] Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy
DOI: https://doi.org/10.21873/anticanres.15312
[2021] [Gut Microbiota and Tumor Immune Microenvironment].
[2021] P48-8 A case of primary lung cancer that led to the diagnosis of SMARCA4-deficient thoracic sarcoid tumor by oncogene panel testing
DOI: https://doi.org/10.1016/j.annonc.2021.05.769
[2021] A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy
DOI: https://doi.org/10.1097/md.0000000000025774

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（62 件）

科研費（0 件）

所属学会・役職（0 件）